{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:06:06Z","timestamp":1774026366395,"version":"3.50.1"},"reference-count":79,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Lung cancer is the commonest malignancy worldwide and the leading cause of cancer death. Half of patients with lung cancer present with advanced disease. The number of systemic therapies including immunotherapy and targeted treatment are rapidly increasing. Despite this, the outcomes for many patients with locally advanced and advanced lung cancer are poor, as many patients are too unwell for treatment. One of the reasons patients with Non-Small Cell Lung Cancer are not fit for treatment is cancer cachexia, which is common (upto 75% of patients) in this group. This metabolic syndrome presents clinically as weight loss (muscle +\/\u2013 fat), decreased physical function (patients less active) and anorexia on a background of systemic inflammation. Currently there is not an optimal management pathway for these patients, however, there is emerging data that multi-modal intervention including nutritional support, physical training and pharmacological therapy may have a role in treating cachexia. This review discusses assessment and intervention in cancer cachexia.<\/jats:p>","DOI":"10.31083\/j.fbl2704129","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:53:52Z","timestamp":1650588832000},"source":"Crossref","is-referenced-by-count":11,"title":["Optimising Outcomes in Non Small Cell Lung Cancer: Targeting Cancer Cachexia"],"prefix":"10.31083","volume":"27","author":[{"given":"Iain","family":"Phillips","sequence":"first","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, EH4 2LF Edinburgh, Scotland, UK"},{"name":"Cancer Research UK Edinburgh Cancer Research Centre, University of Edinburgh, EH4 2XR Edinburgh, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stares","sequence":"first","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, EH4 2LF Edinburgh, Scotland, UK"},{"name":"Cancer Research UK Edinburgh Cancer Research Centre, University of Edinburgh, EH4 2XR Edinburgh, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Allan","sequence":"first","affiliation":[{"name":"Department of Nutrition and Dietetics, Royal Surrey NHS Foundation Trust, GU2 7XX Guildford, Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Sayers","sequence":"first","affiliation":[{"name":"St Columba Hospice, EH5 3RW Edinburgh, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Skipworth","sequence":"first","affiliation":[{"name":"Clinical and Surgical Sciences, University of Edinburgh, Royal Infirmary Edinburgh, EH16 4SA Edinburgh, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Laird","sequence":"first","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, EH4 2LF Edinburgh, Scotland, UK"},{"name":"St Columba Hospice, EH5 3RW Edinburgh, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"ref1","unstructured":"Cancer Research UK. Lung Cancer Survival Statistics. 2022. Available at: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer\/survival#heading-Zero (Accessed: 7 February 2022)."},{"key":"ref2","unstructured":"World Health Organisation. Cancer. 2022. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (Accessed: 7 February 2022)."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pilkington G, Boland A, Brown T, Oyee J, Bagust A, Dickson R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015; 70: 359\u2013367.","DOI":"10.1136\/thoraxjnl-2014-205914"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Journal of the American Medical Association. 2019; 322: 764\u2013774.","DOI":"10.1001\/jama.2019.11058"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50. Journal of Clinical Oncology. 2021; 39: 2339\u20132349.","DOI":"10.1200\/JCO.21.00174"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 2020; 382: 41\u201350.","DOI":"10.1056\/NEJMoa1913662"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet Oncology. 2020; 21: 261\u2013270.","DOI":"10.1016\/S1470-2045(19)30690-4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology. 2020; 31: 1056\u20131064.","DOI":"10.1016\/j.annonc.2020.04.478"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020; 383: 813\u2013824.","DOI":"10.1056\/NEJMoa2005653"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine. 2021; 384: 2371\u20132381.","DOI":"10.1056\/NEJMoa2103695"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020; 383: 944\u2013957.","DOI":"10.1056\/NEJMoa2002787"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet Oncology. 2020; 21: 271\u2013282.","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine. 2018; 379: 2342\u20132350.","DOI":"10.1056\/NEJMoa1809697"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet. 2021; 398: 1344\u20131357.","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020; 383: 1711\u20131723.","DOI":"10.1056\/NEJMoa2027071"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Adizie JB, Khakwani A, Beckett P, Navani N, West D, Woolhouse I, et al. Stage III Non-small Cell Lung Cancer Management in England. Clinical Oncology. 2019; 31: 688\u2013696.","DOI":"10.1016\/j.clon.2019.07.020"},{"key":"ref17","unstructured":"Royal college of Physicians. National Lung Cancer Audit annual report. 2021. Available at: https:\/\/nlca.rcp.ac.uk\/content\/misc\/AR_2019_v2.pdf (Accessed: 7 February 2022)."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Gould MK, Munoz-Plaza CE, Hahn EE, Lee JS, Parry C, Shen E. Comorbidity Profiles and their Effect on Treatment Selection and Survival among Patients with Lung Cancer. Annals of the American Thoracic Society. 2017; 14: 1571\u20131580.","DOI":"10.1513\/AnnalsATS.201701-030OC"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Phillips I, Allan L, Hug A, Westran N, Heinemann C, Hewish M, et al. Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial. 2021. (In press)","DOI":"10.1136\/bmjspcare-2020-002838"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology. 2011; 12: 489\u2013495.","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? British Journal of Cancer. 2004; 90: 1905\u20131911.","DOI":"10.1038\/sj.bjc.6601781"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer\u2013a prospective study examining key clinicopathological factors. Lung Cancer. 2015; 88: 304\u2013309.","DOI":"10.1016\/j.lungcan.2015.03.020"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Bowden JCS, Williams LJ, Simms A, Price A, Campbell S, Fallon MT, et al. Prediction of 90 Day and Overall Survival after Chemoradiotherapy for Lung Cancer: Role of Performance Status and Body Composition. Clinical Oncology. 2017; 29: 576\u2013584.","DOI":"10.1016\/j.clon.2017.06.005"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Caan BJ, Cespedes Feliciano EM, Kroenke CH. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. Cancer Research. 2018; 78: 1906\u20131912.","DOI":"10.1158\/0008-5472.CAN-17-3287"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Khaddour K, Gomez-Perez SL, Jain N, Patel JD, Boumber Y. Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. Frontiers in Oncology. 2020; 10: 576314.","DOI":"10.3389\/fonc.2020.576314"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ardesch FH, Ruiter R, Mulder M, Lahousse L, Stricker BHC, Kiefte-de Jong JC. The Obesity Paradox in Lung Cancer: Associations With Body Size Versus Body Shape. Frontiers in Oncology. 2020; 10: 591110.","DOI":"10.3389\/fonc.2020.591110"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Dolan RD, Abbass T, Sim WMJ, Almasaudi AS, Dieu LB, Horgan PG, et al. Longitudinal Changes in CT Body Composition in Patients Undergoing Surgery for Colorectal Cancer and Associations With Peri-Operative Clinicopathological Characteristics. Frontiers in Nutrition. 2021; 8: 678410.","DOI":"10.3389\/fnut.2021.678410"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Annals of Oncology. 2014; 25: 1492\u20131499.","DOI":"10.1093\/annonc\/mdu085"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Buentzel J, Heinz J, Bleckmann A, Bauer C, R\u00f6ver C, Bohnenberger H, et al. Sarcopenia as Prognostic Factor in Lung Cancer Patients: a Systematic Review and Meta-analysis. Anticancer Research. 2019; 39: 4603\u20134612.","DOI":"10.21873\/anticanres.13640"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical Nutrition. 2017; 36: 1187\u20131196.","DOI":"10.1016\/j.clnu.2017.06.017"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treatment Reviews. 2013; 39: 534\u2013540.","DOI":"10.1016\/j.ctrv.2012.08.003"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clinical Cancer Research. 2013; 19: 5456\u20135464.","DOI":"10.1158\/1078-0432.CCR-13-1066"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Chen Z, Nonaka H, Onishi H, Nakatani E, Sato Y, Funayama S, et al. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study. Journal of Radiation Research. 2021; 62: 457\u2013464.","DOI":"10.1093\/jrr\/rrab021"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ding TG, Thomson F, Stratton C, Cumming K, Barrie C, Maclennan K, et al. Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer. Lung Cancer. 2021; 156: S43.","DOI":"10.1016\/S0169-5002(21)00301-9"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Wang W, Huang Z, Yu Z, Zhuang W, Zheng W, Cai Z, et al. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Frontiers in Oncology. 2020; 10: 572853.","DOI":"10.3389\/fonc.2020.572853"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Chen S, Li R, Zhang Z, Huang Z, Cui P, Jia W, et al. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Translational Lung Cancer Research. 2021; 10: 1397\u20131407.","DOI":"10.21037\/tlcr-21-43"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open. 2020; 10: e035031.","DOI":"10.1136\/bmjopen-2019-035031"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. European Journal of Cancer. 2009; 45: 1950\u20131958.","DOI":"10.1016\/j.ejca.2009.01.023"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non\u2013Small Cell Lung Cancer. JAMA Oncology. 2018; 4: 351\u2013357.","DOI":"10.1001\/jamaoncol.2017.4771"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Petrova MP, Eneva MI, Arabadjiev JI, Conev NV, Dimitrova EG, Koynov KD, et al. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer. BioScience Trends. 2020; 14: 48\u201355.","DOI":"10.5582\/bst.2019.01279"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bharadwaj S, Ginoya S, Tandon P, Gohel TD, Guirguis J, Vallabh H, et al. Malnutrition: laboratory markers vs nutritional assessment. Gastroenterology Report. 2016; 4: 272\u2013280.","DOI":"10.1093\/gastro\/gow013"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. European Journal of Clinical Nutrition. 2020; 74: 1519\u20131535.","DOI":"10.1038\/s41430-020-0629-0"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860\u2013867.","DOI":"10.1038\/nature01322"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, del Fabbro E, Dixon S, et al. Management of Cancer Cachexia: ASCO Guideline. Journal of Clinical Oncology. 2020; 38: 2438\u20132453.","DOI":"10.1200\/JCO.20.00611"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Stares M, Swan A, Cumming K, Ding TE, Leach J, Stratton C, et al. Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. Frontiers in Nutrition. 2021; 8: 734735.","DOI":"10.3389\/fnut.2021.734735"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017; 36: 11\u201348.","DOI":"10.1016\/j.clnu.2016.07.015"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Phillips I, Allan L, Hug A, Westran N, Heinemann C, Hewish M, et al. Symptom burden strongly correlates with the need for a dietitian in advanced NSCLC. Lung Cancer. 2020; 139: S79\u2013S80.","DOI":"10.1016\/S0169-5002(20)30214-2"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Li R, Wu J, Ma M, Pei J, Song Y, Zhang X, et al. Comparison of PG-SGA, SGA and body-composition measurement in detecting malnutrition among newly diagnosed lung cancer patients in stage IIIB\/IV and benign conditions. Medical Oncology (Northwood, London, England). 2011; 28: 689\u2013696.","DOI":"10.1007\/s12032-010-9534-z"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Miller J, Wells L, Nwulu U, Currow D, Johnson MJ, Skipworth RJE. Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: a systematic review. The American Journal of Clinical Nutrition. 2018; 108: 1196\u20131208.","DOI":"10.1093\/ajcn\/nqy244"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Chung M, Phillips I, Allan L, Westran N, Hug A, Evans PM. Early dietitian referral in lung cancer: use of machine learning. BMJ Supportive and Palliative Care. 2022. (In press)","DOI":"10.1136\/bmjspcare-2021-003487"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England Journal of Medicine. 2010; 363: 733\u2013742.","DOI":"10.1056\/NEJMoa1000678"},{"key":"ref52","unstructured":"Macmillan. Prehabilitation Guidance for people with cancer. 2019. Available at: https:\/\/www.macmillan.org.uk\/assets\/prehabilitation-guidance-for-people-with-cancer.pdf (Accessed: 7 February 2022)."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Phillips I, Allan L, Hug A, Westran N, Heinemann C, Hewish M, et al. Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial. BMJ Supportive and Palliative Care. 2021. (In press)","DOI":"10.1136\/bmjspcare-2020-002838"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Baldwin C, Spiro A, McGough C, Norman AR, Gillbanks A, Thomas K, et al. Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. Journal of Human Nutrition and Dietetics. 2011; 24: 431\u2013440.","DOI":"10.1111\/j.1365-277X.2011.01189.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Leedo E, Gade J, Granov S, Mellemgaard A, Klausen TW, Rask K, et al. The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: a Randomized Controlled Trial. Nutrition and Cancer. 2017; 69: 444\u2013453.","DOI":"10.1080\/01635581.2017.1283421"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bozzetti F. Does nutrition support during chemotherapy increase long-term survival of cancer patients? Lessons from the past and future perspectives. Supportive Care in Cancer. 2021; 29: 7269\u20137277.","DOI":"10.1007\/s00520-021-06213-w"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2016; 12: CD005305.","DOI":"10.1002\/14651858.CD005305.pub4"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Cavalheri V, Burtin C, Formico VR, Nonoyama ML, Jenkins S, Spruit MA, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2019; 6: CD009955.","DOI":"10.1002\/14651858.CD009955.pub3"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galv\u00e3o DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database of Systematic Reviews. 2019; 2: CD012685.","DOI":"10.1002\/14651858.CD012685.pub2"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncology. 2005; 23: 8500\u20138511.","DOI":"10.1200\/JCO.2005.01.8010"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines\u2606. ESMO Open. 2021; 6: 100092.","DOI":"10.1016\/j.esmoop.2021.100092"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Pradhan G, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. Current Opinion in Clinical Nutrition and Metabolic Care. 2013; 16: 619\u2013624.","DOI":"10.1097\/MCO.0b013e328365b9be"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non\u2010small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle. 2021; 12: 14\u201316.","DOI":"10.1002\/jcsm.12675"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, et al. A multicenter, open\u2010label, single\u2010arm study of anamorelin (ONO\u20107643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019; 125: 4294\u20134302.","DOI":"10.1002\/cncr.32406"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Supportive Care in Cancer. 2016; 24: 3495\u20133505.","DOI":"10.1007\/s00520-016-3144-z"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology. 2016; 17: 519\u2013531.","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology. 2017; 28: 1949\u20131956.","DOI":"10.1093\/annonc\/mdx192"},{"key":"ref68","unstructured":"European Medicines Agency. Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride), in European Medicines Agency. 2017. Available at: URL (Accessed: 7 February 2022)."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia V, L\u00f3pez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. The Cochrane Database of Systematic Reviews. 2013; 2013: CD004310.","DOI":"10.1002\/14651858.CD004310.pub3"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ruiz-Garc\u00eda V, L\u00f3pez-Briz E, Carbonell-Sanchis R, Bort-Mart\u00ed S, Gonz\u00e1lvez-Perales JL. Megestrol acetate for cachexia-anorexia syndrome. a systematic review. Journal of Cachexia, Sarcopenia and Muscle. 2018; 9: 444\u2013452.","DOI":"10.1002\/jcsm.12292"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. Journal of Clinical Oncology. 2006; 24: 3394\u20133400.","DOI":"10.1200\/JCO.2005.05.1847"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Annals of Oncology. 2011; 22: 2086\u20132093.","DOI":"10.1093\/annonc\/mdq727"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology. 2002; 20: 567\u2013573.","DOI":"10.1200\/JCO.2002.20.2.567"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"M\u00fccke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018; 9: 220\u2013234.","DOI":"10.1002\/jcsm.12273"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Solheim TS, Fearon KCH, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncologica. 2013; 52: 6\u201317.","DOI":"10.3109\/0284186X.2012.724536"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Hall CC, Cook J, Maddocks M, Skipworth RJE, Fallon M, Laird BJ. Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review. Supportive Care in Cancer. 2019; 27: 2371\u20132384.","DOI":"10.1007\/s00520-019-04749-6"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, et al. Cancer cachexia: rationale for the MENAC (Multimodal\u2014Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Supportive & Palliative Care. 2018; 8: 258\u2013265.","DOI":"10.1136\/bmjspcare-2017-001440"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle. 2018; 8: 778\u2013788.","DOI":"10.1002\/jcsm.12201"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hall CC, Skipworth RJE, Blackwood H, Brown D, Cook J, Diernberger K, et al. A randomized, feasibility trial of an exercise and nutrition-based rehabilitation programme (ENeRgy) in people with cancer. Journal of Cachexia, Sarcopenia and Muscle. 2021; 12: 2034\u20132044.","DOI":"10.1002\/jcsm.12806"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:58:19Z","timestamp":1732708699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00470-1"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2704129","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"article-number":"129"}}